https://www.selleckchem.com/pr....oducts/brigatinib-ap
36% (11/89) were pre-extensively drug-resistant TB (pre-XDR-T and 77.53% (69/89) were XDR-TB. The rrs mutations were found 82.02% (73/89) in amikacin-resistant M. tuberculosis clinical isolates. The A1401 G alteration in rrs gene was the most dominant mutation (80.90%; 72/89). Five mutations were detected as new in rrs, tap, and whiB7. Notably, 13.48% (12/89) amikacin-resistant isolates had no known mutation in these genes. CONCLUSIONS Our data reveal that the rrs mutation is a predominant molecular marker of amikacin resis
Like
Comment
Share
